Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025.

Authors

Jiayi Du, Sophie Li, Ivan F N Hung, Joseph T Wu, Kathy Leung

Published in

EClinicalMedicine. Volume 96. Pages 104017. Epub Jun 16, 2026.

Abstract

Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infection (LRTI) and mortality among infants and older adults globally. The recent approval of long-acting monoclonal antibodies (mAbs) and prefusion F protein-based vaccines marks a significant shift in the prevention landscape. This systematic review aims to synthesise current evidence regarding the efficacy and real-world effectiveness of RSV interventions.
We searched PubMed, Scopus, and Web of Science for randomised controlled trials and observational studies published between January 1, 2018, and September 8, 2025, that evaluated palivizumab, nirsevimab, and RSV vaccines in infants, pregnant women, and older adults. The primary outcome was RSV-associated lower respiratory tract infection (RSV-LRTI) hospitalisation. Pooled efficacy and effectiveness were estimated using random-effects meta-analysis. This study is registered with PROSPERO, CRD420261285934.
In infants, palivizumab demonstrated effectiveness against RSV-LRTI hospitalisation up to 180 days post-discharge that varied substantially by analytical approach: OR-based studies yielded a pooled effectiveness of approximately 81% (95% CI: 57%-91%), while rate-ratio-based cohort studies produced a non-statistically significant estimate of 34% (95% CI: -17%-63%). Nirsevimab showed pooled efficacy/effectiveness of approximately 80-85% through 150-180 days post-dose, with consistent results across OR-based (84%, 95% CI: 78%-88%) and rate-ratio-based analyses (79%, 95% CI: 72%-85%). Maternal vaccine efficacy within 180 days after birth was 72% (95% CI: 61%-79%) against severe RSV-LRTI compared to 67% (95% CI: 53%-77%) against RSV-LRTI hospitalisations. In older adults, vaccination demonstrated robust protection during the first RSV season following vaccination, with a pooled vaccine effectiveness of 77% (95% CI: 69%-82%) against RSV-LRTI hospitalisations.
Prophylactic strategies demonstrate effectiveness in reducing the burden of RSV-associated diseases. Both palivizumab and nirsevimab provide robust protection against RSV-LRTI hospitalisation in their respective target populations. Additionally, both maternal and older adult vaccinations are effective in reducing RSV-associated diseases.
General Research Fund, AIR@InnoHK.

PMID:
42339311
Bibliographic data and abstract were imported from PubMed on 24 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.